Repligen Corporation, a life sciences company focused on bioprocessing technology, appointed Jason Garland chief financial officer, effective September 25, 2023. He succeeds retiring CFO Jon Snodgres.

Garland is joining Repligen from his most recent role with Integer Holdings Corp., where he served for nearly five years as executive vice president and CFO.

In his new role, Garland will act as a key partner to the business, with responsibility for all corporate finance and audit functions, capital markets and M&A transactions, financial planning and analysis, budgeting, and risk management.

Garland brings more than 25 years of relevant experience at large, multi-site organizations, including a division-level role within General Electric Co. where he served as the CFO of a $4 billion dollar business with over 40 global manufacturing sites.

In his most recent CFO role at Integer, he helped scale the enterprise to $1.4 billion in revenue, and he and his team supported Integer in evaluating and integrating four acquisitions. At Integer, Garland also assumed executive sponsorship of the company’s business process excellence initiative focused on standardizing and optimizing all non-manufacturing processes.

Tony Hunt, President, and CEO at Repligen, said, “Jason’s financial acumen and rich experience as a business-driven, operational CFO at both large global and growth-focused organizations will serve Repligen well, as we continue to focus on driving success for our company through innovation, including M&A, while delivering above-industry growth and strong financial performance.”

Garland said, “I am thrilled to be joining Repligen, and look forward to applying my experience to support the Company’s financial and operational performance. I look forward to meeting my new colleagues and working to execute on transactions and strategies that can build on Repligen’s innovation edge in the bioprocessing market.”